|AHFS/Drugs.com||Consumer Drug Information|
|By mouth (capsules)|
|Metabolism||Hepatic (demethylation and glucuronidation)|
|Elimination half-life||1.4–2.6 hours (mesuximide)|
28–38 hours (active metabolite)
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||203.241 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland) and Celontin (United States). The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.
- Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Archived from the original on April 22, 2005. Retrieved August 21, 2006.
- Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014.
- Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ (November 1979). "Plasma concentrations of phensuximide, methsuximide, and their metabolites in relation to clinical efficacy". Neurology. 29 (11): 1509–13. doi:10.1212/wnl.29.11.1509. PMID 116142.